FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324332959> ?p ?o ?g. }

• W4324332959 endingPage "815" @default.
• W4324332959 startingPage "806" @default.
• W4324332959 abstract "In the USA, oral nirmatrelvir-ritonavir is authorised for use in patients aged 12 years or older with mild-to-moderate COVID-19 who are at risk of progression to severe disease and hospitalisation. We aimed to establish the effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and death in people with COVID-19 in an outpatient prescribing context in the USA.In this matched observational outpatient cohort study in the Kaiser Permanente Southern California (CA, USA) health-care system, data were extracted from electronic health records of non-hospitalised patients aged 12 years or older who received a positive SARS-CoV-2 PCR test result (their index test) between April 8 and Oct 7, 2022, and had not received another positive test result within the preceding 90 days. We compared outcomes between people who received nirmatrelvir-ritonavir and those who did not receive nirmatrelvir-ritonavir by matching cases by date, age, sex, clinical status (including care received, the presence or absence of acute COVID-19 symptoms at testing, and time from symptom onset to testing), vaccination history, comorbidities, health-care seeking during the previous year, and BMI. Our primary endpoint was the estimated effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions or death within 30 days of a positive test for SARS-CoV-2.7274 nirmatrelvir-ritonavir recipients and 126 152 non-recipients with positive SARS-CoV-2 tests were included in our study. 5472 (75·2%) treatment recipients and 84 657 (67·1%) non-recipients were tested within 5 days of symptom onset. Nirmatrelvir-ritonavir had an overall estimated effectiveness of 53·6% (95% CI 6·6-77·0) in preventing hospital admission or death within 30 days of a positive test for SARS-CoV-2, which increased to 79·6% (33·9-93·8) when nirmatrelvir-ritonavir was dispensed within 5 days of symptom onset. Within the subgroup of patients tested within 5 days of symptom onset and whose treatment was dispensed on the day of their test, the estimated effectiveness of nirmatrelvir-ritonavir was 89·6% (50·2-97·8).In a setting with high levels of COVID-19 vaccine uptake, nirmatrelvir-ritonavir effectively reduced the risk of hospital admission or death within 30 days of a positive outpatient SARS-CoV-2 test.US Centers for Disease Control and Prevention and US National Institutes of Health." @default.
• W4324332959 created "2023-03-16" @default.
• W4324332959 creator A5002800668 @default.
• W4324332959 creator A5006442640 @default.
• W4324332959 creator A5009305511 @default.
• W4324332959 creator A5013063227 @default.
• W4324332959 creator A5015228397 @default.
• W4324332959 creator A5021589539 @default.
• W4324332959 creator A5031960337 @default.
• W4324332959 creator A5038341778 @default.
• W4324332959 creator A5047550196 @default.
• W4324332959 creator A5073430426 @default.
• W4324332959 creator A5075087643 @default.
• W4324332959 creator A5089964898 @default.
• W4324332959 date "2023-07-01" @default.
• W4324332959 modified "2023-10-14" @default.
• W4324332959 title "Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system" @default.
• W4324332959 cites W1969600340 @default.
• W4324332959 cites W1977247044 @default.
• W4324332959 cites W2165037395 @default.
• W4324332959 cites W3048371719 @default.
• W4324332959 cites W3161135492 @default.
• W4324332959 cites W3176391331 @default.
• W4324332959 cites W4211101039 @default.
• W4324332959 cites W4220886953 @default.
• W4324332959 cites W4225015742 @default.
• W4324332959 cites W4226236384 @default.
• W4324332959 cites W4281784908 @default.
• W4324332959 cites W4281988270 @default.
• W4324332959 cites W4283258331 @default.
• W4324332959 cites W4286380684 @default.
• W4324332959 cites W4288714695 @default.
• W4324332959 cites W4293198902 @default.
• W4324332959 cites W4293280590 @default.
• W4324332959 cites W4293413604 @default.
• W4324332959 cites W4298145582 @default.
• W4324332959 cites W4303423758 @default.
• W4324332959 cites W4308796781 @default.
• W4324332959 cites W4309698385 @default.
• W4324332959 cites W4310464163 @default.
• W4324332959 doi "https://doi.org/10.1016/s1473-3099(23)00118-4" @default.
• W4324332959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36933565" @default.
• W4324332959 hasPublicationYear "2023" @default.
• W4324332959 type Work @default.
• W4324332959 citedByCount "14" @default.
• W4324332959 countsByYear W43243329592023 @default.
• W4324332959 crossrefType "journal-article" @default.
• W4324332959 hasAuthorship W4324332959A5002800668 @default.
• W4324332959 hasAuthorship W4324332959A5006442640 @default.
• W4324332959 hasAuthorship W4324332959A5009305511 @default.
• W4324332959 hasAuthorship W4324332959A5013063227 @default.
• W4324332959 hasAuthorship W4324332959A5015228397 @default.
• W4324332959 hasAuthorship W4324332959A5021589539 @default.
• W4324332959 hasAuthorship W4324332959A5031960337 @default.
• W4324332959 hasAuthorship W4324332959A5038341778 @default.
• W4324332959 hasAuthorship W4324332959A5047550196 @default.
• W4324332959 hasAuthorship W4324332959A5073430426 @default.
• W4324332959 hasAuthorship W4324332959A5075087643 @default.
• W4324332959 hasAuthorship W4324332959A5089964898 @default.
• W4324332959 hasBestOaLocation W43243329591 @default.
• W4324332959 hasConcept C126322002 @default.
• W4324332959 hasConcept C142462285 @default.
• W4324332959 hasConcept C151730666 @default.
• W4324332959 hasConcept C187212893 @default.
• W4324332959 hasConcept C194828623 @default.
• W4324332959 hasConcept C23131810 @default.
• W4324332959 hasConcept C2779298103 @default.
• W4324332959 hasConcept C2779343474 @default.
• W4324332959 hasConcept C2993143319 @default.
• W4324332959 hasConcept C3013748606 @default.
• W4324332959 hasConcept C512399662 @default.
• W4324332959 hasConcept C71924100 @default.
• W4324332959 hasConcept C86803240 @default.
• W4324332959 hasConceptScore W4324332959C126322002 @default.
• W4324332959 hasConceptScore W4324332959C142462285 @default.
• W4324332959 hasConceptScore W4324332959C151730666 @default.
• W4324332959 hasConceptScore W4324332959C187212893 @default.
• W4324332959 hasConceptScore W4324332959C194828623 @default.
• W4324332959 hasConceptScore W4324332959C23131810 @default.
• W4324332959 hasConceptScore W4324332959C2779298103 @default.
• W4324332959 hasConceptScore W4324332959C2779343474 @default.
• W4324332959 hasConceptScore W4324332959C2993143319 @default.
• W4324332959 hasConceptScore W4324332959C3013748606 @default.
• W4324332959 hasConceptScore W4324332959C512399662 @default.
• W4324332959 hasConceptScore W4324332959C71924100 @default.
• W4324332959 hasConceptScore W4324332959C86803240 @default.
• W4324332959 hasFunder F4320332161 @default.
• W4324332959 hasFunder F4320332162 @default.
• W4324332959 hasFunder F4320337355 @default.
• W4324332959 hasIssue "7" @default.
• W4324332959 hasLocation W43243329591 @default.
• W4324332959 hasLocation W43243329592 @default.
• W4324332959 hasLocation W43243329593 @default.
• W4324332959 hasLocation W43243329594 @default.
• W4324332959 hasOpenAccess W4324332959 @default.
• W4324332959 hasPrimaryLocation W43243329591 @default.
• W4324332959 hasRelatedWork W2025193597 @default.
• W4324332959 hasRelatedWork W2042489430 @default.

• next